XML 26 R4.htm IDEA: XBRL DOCUMENT v3.24.3Close
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 1,699.2 $ 1,049.9
Inventory 2,469.2 2,527.4
Other current assets 674.0 1,182.0
Total current assets 6,830.5 6,859.3
Property, plant and equipment, net 3,210.9 3,309.7
Operating lease assets 380.4 420.0
Intangible assets, net 9,805.5 8,363.0
Goodwill 6,485.8 6,219.2
Deferred tax asset 968.7 928.6
Investments and other assets 631.4 745.0
Total assets 28,313.2 26,844.8 Close
Current liabilities:    
Current portion notes payable and term loan 1,748.1 150.0
Taxes payable 499.1 257.4
Accounts payable 422.7 403.3
Accrued expense and other 2,755.1 2,623.6
Total current liabilities 5,425.0 3,434.3
Notes payable and term loan 4,545.8 6,788.2
Deferred tax liability 882.4 641.8
Long-term operating lease liabilities 357.0 400.0
Other long-term liabilities 744.1 781.1
Total liabilities 11,954.3 12,045.4 Close
Commitments, contingencies and guarantees
Biogen Inc. shareholders’ equity:    
Preferred stock, par value $0.001 per share 0.0 0.0
Common stock, par value $0.0005 per share 0.1 0.1
Additional paid-in capital 488.5 302.5
Accumulated other comprehensive income (loss) (145.7) (153.7)
Retained earnings 18,993.1 17,627.6
Treasury stock, at cost (2,977.1) (2,977.1)
Total equity 16,358.9 14,799.4 Close
Total liabilities and equity 28,313.2 26,844.8
Nonrelated Party    
Current assets:    
Accounts receivable, net of allowance for doubtful accounts of $2.0 and $2.4, respectively 1,536.2 1,664.1
Related Party    
Current assets:    
Accounts receivable, net of allowance for doubtful accounts of $2.0 and $2.4, respectively $ 451.9 $ 435.9